$14.28
-0.45-3.05%
At Close: -
$14.28
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Arcus Biosciences
RCUSNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Arcus Biosciences (NYSE:RCUS) Stock, Analyst Ratings, Price Targets, Forecasts
Arcus Biosciences Inc has a consensus price target of $43.71 based on the ratings of 15 analysts. The high is $100 issued by SVB Leerink on November 18, 2021. The low is $23 issued by B of A Securities on September 5, 2023. The 3 most-recent analyst ratings were released by Barclays, Truist Securities, and Citigroup on July 8, 2024, June 24, 2024, and June 3, 2024, respectively. With an average price target of $35.67 between Barclays, Truist Securities, and Citigroup, there's an implied 149.77% upside for Arcus Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Truist Securities
Citigroup
Wedbush
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Arcus Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/08/2024 | Buy Now | 75.07% | Barclays | Peter Lawson | $35 → $25 | Maintains | Overweight | Get Alert |
| 07/05/2024 | Buy Now | — | Cantor Fitzgerald | Alethia Young | — | Reiterates | → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 208.12% | Truist Securities | Asthika Goonewardene | $50 → $44 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 166.11% | Citigroup | Yigal Nochomovitz | $36 → $38 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 110.08% | Wedbush | Robert Driscoll | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 03/25/2024 | Buy Now | 250.14% | Truist Securities | Robyn Karnauskas | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | 110.08% | Wedbush | Robert Driscoll | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 110.08% | Wedbush | Robert Driscoll | $36 → $30 | Maintains | Outperform | Get Alert |
| 01/30/2024 | Buy Now | 194.12% | Mizuho | Mara Goldstein | $51 → $42 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | 152.1% | Wedbush | Robert Driscoll | → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/13/2023 | Buy Now | 145.1% | Morgan Stanley | Terence Flynn | $38 → $35 | Maintains | Overweight | Get Alert |
| 11/08/2023 | Buy Now | 152.1% | Cantor Fitzgerald | Li Watsek | $46 → $36 | Maintains | Overweight | Get Alert |
| 10/03/2023 | Buy Now | 257.14% | Mizuho | Mara Goldstein | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 222.13% | Cantor Fitzgerald | Alethia Young | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 222.13% | Cantor Fitzgerald | Alethia Young | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2023 | Buy Now | 250.14% | Truist Securities | Robyn Karnauskas | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 61.06% | B of A Securities | Jason Zemansky | $21 → $23 | Maintains | Neutral | Get Alert |
| 08/24/2023 | Buy Now | 208.12% | Citigroup | Yigal Nochomovitz | $41 → $44 | Maintains | Buy | Get Alert |
| 08/23/2023 | Buy Now | 390.2% | BTIG | Kaveri Pohlman | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | 257.14% | Mizuho | Mara Goldstein | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 166.11% | Morgan Stanley | Terence Flynn | $40 → $38 | Maintains | Overweight | Get Alert |
| 07/12/2023 | Buy Now | 222.13% | Cantor Fitzgerald | Alethia Young | → $46 | Reinstates | Overweight → Overweight | Get Alert |
| 05/26/2023 | Buy Now | 187.11% | Citigroup | Yigal Nochomovitz | $40 → $41 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 152.1% | Wedbush | Robert Driscoll | → $36 | Reiterates | → Outperform | Get Alert |
| 03/17/2023 | Buy Now | 257.14% | Mizuho | Mara Goldstein | → $51 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 180.11% | Citigroup | Yigal Nochomovitz | $42 → $40 | Maintains | Buy | Get Alert |
| 12/21/2022 | Buy Now | 145.1% | Barclays | Peter Lawson | $60 → $35 | Maintains | Overweight | Get Alert |
| 12/20/2022 | Buy Now | 194.12% | Citigroup | Yigal Nochomovitz | $37 → $42 | Maintains | Buy | Get Alert |
| 11/23/2022 | Buy Now | 159.1% | Citigroup | Yigal Nochomovitz | $40 → $37 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 131.09% | B of A Securities | Jason Zemansky | → $33 | Initiates | → Neutral | Get Alert |
| 11/03/2022 | Buy Now | 166.11% | SVB Leerink | Daina Graybosch | $40 → $38 | Maintains | Outperform | Get Alert |
| 10/11/2022 | Buy Now | 180.11% | Morgan Stanley | Terence Flynn | → $40 | Initiates | → Overweight | Get Alert |
| 08/18/2022 | Buy Now | 180.11% | Citigroup | Yigal Nochomovitz | $48 → $40 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | 243.14% | SVB Leerink | Daina Graybosch | $66 → $49 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | 250.14% | Truist Securities | Robyn Karnauskas | $77 → $50 | Maintains | Buy | Get Alert |
| 05/12/2022 | Buy Now | 96.08% | Goldman Sachs | Salveen Richter | $48 → $28 | Maintains | Neutral | Get Alert |
| 05/11/2022 | Buy Now | 236.13% | Goldman Sachs | Salveen Richter | $43 → $48 | Maintains | Neutral | Get Alert |
| 11/19/2021 | Buy Now | 271.15% | Citigroup | — | — | Maintains | Buy | Get Alert |
| 11/19/2021 | Buy Now | 320.17% | Barclays | Peter Lawson | — | Maintains | Overweight | Get Alert |
| 11/18/2021 | Buy Now | 600.28% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
| 11/09/2021 | Buy Now | 236.13% | Barclays | Peter Lawson | — | Maintains | Overweight | Get Alert |
| 08/06/2021 | Buy Now | 376.19% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Arcus Biosciences (RCUS) stock?
The latest price target for Arcus Biosciences (NYSE:RCUS) was reported by Barclays on July 8, 2024. The analyst firm set a price target for $25.00 expecting RCUS to rise to within 12 months (a possible 75.07% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcus Biosciences (RCUS)?
The latest analyst rating for Arcus Biosciences (NYSE:RCUS) was provided by Barclays, and Arcus Biosciences maintained their overweight rating.
When was the last upgrade for Arcus Biosciences (RCUS)?
There is no last upgrade for Arcus Biosciences
When was the last downgrade for Arcus Biosciences (RCUS)?
There is no last downgrade for Arcus Biosciences.
When is the next analyst rating going to be posted or updated for Arcus Biosciences (RCUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcus Biosciences was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
Is the Analyst Rating Arcus Biosciences (RCUS) correct?
While ratings are subjective and will change, the latest Arcus Biosciences (RCUS) rating was a maintained with a price target of $35.00 to $25.00. The current price Arcus Biosciences (RCUS) is trading at is $14.28, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.